Exact Sciences posts positive data on Cologuard 2.0 ahead of readouts on rival tests

Exact Sciences has released results from a study of the updated Cologuard test it is developing to cement its position in the colorectal cancer screening market. The study, which Exact Sciences designed to mimic its ongoing pivotal trial, found Cologuard 2.0 has a lower false positive rate than the current product and is better at detecting precancerous lesions.